The high level of lncRNA AFAP1‐AS1 contributes to the acquisition of malignant phenotypes of cisplatin resistance NSCLC Cells by interacting with EZH2 to activate PI3K/AKT pathway (Figure 2(e)) [30]. The gene discussed is EZH2; the disease is non-small cell lung carcinoma.